INVO Fertility 2025 Q3 Earnings 94.9% EPS Improvement Amid Widening Net Loss

INVO Fertility (Nasdaq: IVF) reported its fiscal 2025 Q3 earnings on Nov 17, 2025, showing 22.6% revenue growth to $1.76 million but persistent net losses. The company narrowed its per-share loss by 94.9% to $0.77, while the net loss widened by 62.2% to $2.64 million, underscoring ongoing financial challenges. Management maintained a cautious outlook, emphasizing strategic acquisitions and operational efficiencies to drive long-term growth despite the deteriorating profitability.

Revenue

Clinic operations drove the majority of revenue, generating $1.72 million, while product sales contributed an additional $34,871, bringing the total to $1.76 million. The clinic revenue surged 21% year-over-year, reflecting expanded patient access and service diversification, while product revenue, primarily from INVOcell devices, grew 130% year-over-year, driven by pricing improvements and training initiatives.

Earnings/Net Income

INVO Fertility narrowed its per-share loss to $0.77 in Q3 2025 from $15.11 in Q3 2024, a 94.9% improvement. However, the net loss expanded by 62.2% to $2.64 million, reflecting higher operational costs and strategic investments. Despite the EPS improvement, the widening net loss highlights the company’s struggle to convert top-line growth into profitability, with losses sustained for seven consecutive years.

Price Action

Following the earnings report, INVO Fertility’s stock experienced a 7.29% decline in a single trading day, with the downward trend intensifying to a 16.73% drop over the subsequent full trading week. The month-to-date performance was particularly volatile, as the stock plummeted 67.29%, reflecting investor concern over the company’s persistent losses and uncertain profitability path.

CEO Commentary

Steve Shum, CEO of INVO Fertility, highlighted 23% organic clinic growth in Q3 2025, driven by increased patient flow, enhanced marketing, and telehealth expansion. He emphasized a strategic pipeline of acquisitions, including an expected deal in the coming months, and noted 130% year-over-year INVOcell device revenue growth. The CEO also underscored partnerships like Heidi Health’s AI-powered scribe integration as critical to improving operational efficiency and profitability.

Guidance

The company expects to complete at least one acquisition in the coming months, leveraging its public-company platform to attract fertility clinics. Management remains focused on scaling through strategic partnerships, operational efficiencies, and policy-driven access to IVF. While expressing confidence in organic clinic performance and federal policy momentum, no specific revenue or margin targets were provided, leaving the path to profitability uncertain.

Additional News

INVO Fertility delayed its Q3 2025 Form 10-Q filing, citing challenges in compiling financial data. The company also announced a non-timely filing with the SEC, raising concerns about regulatory compliance. Additionally, a federal policy update in October 2025 expanded access to standalone infertility benefits, which CEO Steve Shum described as a “step forward” for industry growth. These developments, coupled with the stock’s volatile price action, highlight both operational hurdles and potential catalysts for the company’s long-term strategy.